SCHEMBL1507749

SCHEMBL1507749

CCCCNCc1ccc2cccc(NC(=O)OC(C)(C)C)c2n1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
PLAU P00749 1/20 0.38
CNR2 P34972 1/20 0.38
PDE10A Q9Y233 7/20 0.38
MAPKAPK2 P49137 1/20 0.37
PDE4D Q08499 1/20 0.36
IL6 P05231 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
MAPT P10636 1/20 0.36
CTSK P43235 1/20 0.36
NQO2 P16083 1/20 0.35
KDM4E B2RXH2 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507944 0.90 PLAU (0.43) TP53PIM1PIM2PLAUPDE10A
SCHEMBL1507889 0.82 TP53 (0.40) TP53POLBPIM1PIM2PLAU
SCHEMBL1507701 0.80 PLAU (0.42) TP53PIM1PIM2PLAUPDE10A
SCHEMBL22765025 0.79 PLAU (0.41) TP53PIM1PIM2PLAUPDE10A
SCHEMBL5959295 0.75 PLAU (0.49) TP53PLAUMAPT
SCHEMBL30471577 0.75 MAPT (0.57) TP53POLBMAPTKMT2A
SCHEMBL7748081 0.75 MAPT (0.57) TP53POLBMAPTKMT2A
SCHEMBL14551175 0.75 PLAU (0.46) POLBPIM1PIM2PLAUMAPKAPK2
SCHEMBL30711802 0.73 TMEM97 (0.40) MAPKAPK2
SCHEMBL20838489 0.73 TMEM97 (0.40) MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US disclosed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
EP-2289891-A2 Novel polyquinoline derivates and the therapeutic use thereof Palumed S.A. (FR) 2011-03-02 EP disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF HTT, APP, PSEN1 TP53 2072/4885POLB 3368/4885PIM1 4677/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 TP53 3502/4885POLB 2526/4885PIM1 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.